Tags

Type your tag names separated by a space and hit enter

Treatment of leishmaniasis with miltefosine: 2008 status.
Expert Opin Drug Metab Toxicol. 2008 Sep; 4(9):1209-16.EO

Abstract

BACKGROUND

Miltefosine is the first recognized oral treatment for leishmaniasis. It was first registered, in 2002, for Indian visceral leishmaniasis, and was reviewed by the present author in 2005.

QUESTION

Miltefosine is now being used for the full range of clinical leishmaniasis. The present review addresses non-clinical and clinical advances since 2005.

METHODS

PubMed was accessed for all articles on miltefosine from 2005 to 2008.

RESULTS/CONCLUSIONS

Miltefosine is effective and can be recommended for visceral disease in India and in Ethiopia, and for cutaneous disease in Colombia and Bolivia. For unusual forms of disease that require long periods of treatment such as diffuse cutaneous leishmaniasis and post-kala-azar dermal leishmaniasis, oral miltefosine is probably the treatment of choice.

Authors+Show Affiliations

Jbe9320457@aol.com

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

18721114

Citation

Berman, Jonathan Josh. "Treatment of Leishmaniasis With Miltefosine: 2008 Status." Expert Opinion On Drug Metabolism & Toxicology, vol. 4, no. 9, 2008, pp. 1209-16.
Berman JJ. Treatment of leishmaniasis with miltefosine: 2008 status. Expert Opin Drug Metab Toxicol. 2008;4(9):1209-16.
Berman, J. J. (2008). Treatment of leishmaniasis with miltefosine: 2008 status. Expert Opinion On Drug Metabolism & Toxicology, 4(9), 1209-16. https://doi.org/10.1517/17425255.4.9.1209
Berman JJ. Treatment of Leishmaniasis With Miltefosine: 2008 Status. Expert Opin Drug Metab Toxicol. 2008;4(9):1209-16. PubMed PMID: 18721114.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Treatment of leishmaniasis with miltefosine: 2008 status. A1 - Berman,Jonathan Josh, PY - 2008/8/30/pubmed PY - 2008/10/11/medline PY - 2008/8/30/entrez SP - 1209 EP - 16 JF - Expert opinion on drug metabolism & toxicology JO - Expert Opin Drug Metab Toxicol VL - 4 IS - 9 N2 - BACKGROUND: Miltefosine is the first recognized oral treatment for leishmaniasis. It was first registered, in 2002, for Indian visceral leishmaniasis, and was reviewed by the present author in 2005. QUESTION: Miltefosine is now being used for the full range of clinical leishmaniasis. The present review addresses non-clinical and clinical advances since 2005. METHODS: PubMed was accessed for all articles on miltefosine from 2005 to 2008. RESULTS/CONCLUSIONS: Miltefosine is effective and can be recommended for visceral disease in India and in Ethiopia, and for cutaneous disease in Colombia and Bolivia. For unusual forms of disease that require long periods of treatment such as diffuse cutaneous leishmaniasis and post-kala-azar dermal leishmaniasis, oral miltefosine is probably the treatment of choice. SN - 1742-5255 UR - https://www.unboundmedicine.com/medline/citation/18721114/Treatment_of_leishmaniasis_with_miltefosine:_2008_status_ L2 - https://www.tandfonline.com/doi/full/10.1517/17425255.4.9.1209 DB - PRIME DP - Unbound Medicine ER -